Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR Abstract #1721

Introduction: In advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin analogs treatment rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by Response Evaluation Criteria in Solid Tumors (RECIST) for an ‘objective response’. The implication of Stable Disease (SD) as an additional indicator of therapeutic effect is often uncertain.
Aim(s): We sought to determine a threshold as the reliable early indicator which may derive PFS benefit from this therapy.
Materials and methods: Thirty-three patients with well differentiated advanced GEP-NETs (WDGEP-NETs) treated with octreotide LAR underwent thoracic, abdominal and pelvic computed tomography at baseline and at first follow-up after therapy were enrolled. Thresholds from -30% to +20% was defined by the best change in the sum of the longest diameters (ΔSLD) of target lesions, Kaplan–Meier and receiver operating characteristic (ROC) analysis were used to determine the optimal size threshold to distinguish ‘responders’ from ‘non-responders’ with respect to significant improvement in PFS.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J

To read results and conclusion, please login ...

Further abstracts you may be interested in

#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C
#458 Octreotide Long-Acting ReleaseTherapy for Patients with Functional and Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis in Chang-Gung Memorial Hospital
Introduction: Reports of octreotide therapy for symptomatic control in patients with functioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Asia are lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Chia-Hsun Hsieh
#795 Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET): A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)
Introduction: OCT has shown antitumor activity and significantly prolonged time to tumor progression vs PBO in pts with metastatic midgut NET (PROMID).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Jonathan R Strosberg
#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors
Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang X, Li Y L, Shi Y F, Chen Y Y, ...
#496 Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients with Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis
Introduction: In RADIANT-2, patients (pts) with advanced neuroendocrine tumors (NET) on Everolimus (E, 10 mg/d) + octreotide LAR (O, 30 mg q28d) had clinically meaningful improvement in progression-free survival (PFS) v. placebo (P)+O (16.4 mo v. 11.3 mo, respectively).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.